Adipotide (FTPP) vs HGH Fragment 176-191
Adipotide (FTPP) (Pro-apoptotic peptidomimetic (prohibitin-targeting)) and HGH Fragment 176-191 (Modified GH-fragment peptide) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | Adipotide (FTPP) | HGH Fragment 176-191 |
|---|---|---|
| Compound class | Pro-apoptotic peptidomimetic (prohibitin-targeting) | Modified GH-fragment peptide |
| Research category | Metabolic & Mitochondrial | Metabolic & Mitochondrial |
| Length (amino acids) | Not documented | 15 amino acids |
| Molecular weight | ~2611 g/mol (approx. C152H252N44O42) | ~1817 g/mol |
| Half-life | Not documented | ~15-20 minutes (reported) |
| Origin | Adipotide (also called FTPP, prohibitin-targeting peptide-1) is a synthetic peptidomimetic combining a prohibitin-targeting sequence (CKGGRAKDC) with a pro-apoptotic amphipathic domain (KLAKLAK)2 via a linker. It was developed as an experimental agent to target the vasculature of white adipose tissue. | HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal region (residues 176-191) of human growth hormone. This portion of the GH molecule was identified as carrying the hormone's lipolytic activity. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How Adipotide (FTPP) works
The CKGGRAKDC domain binds a prohibitin/ANXA2 receptor complex found on the endothelium (blood vessels) supplying white adipose tissue. Once localized, the D(KLAKLAK)2 domain disrupts mitochondrial membranes and triggers apoptosis, ablating the blood supply to fat depots. In animal studies this produced rapid loss of adipose tissue.
How HGH Fragment 176-191 works
The fragment reproduces the C-terminal, lipolytic-associated region of GH while lacking the domains responsible for GH's growth-promoting and insulin-antagonizing actions. In preclinical models this region has been reported to stimulate fat breakdown (lipolysis) and reduce lipogenesis. It is not intact growth hormone and is not reported to reproduce GH's systemic growth effects.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
Adipotide (FTPP)
HGH Fragment 176-191
What sets each apart
Adipotide (FTPP)
Unlike the lipolytic GH fragments, adipotide does not stimulate fat metabolism; it destroys the blood vessels feeding fat tissue via a targeted pro-apoptotic mechanism.
HGH Fragment 176-191
This is the native GH C-terminal fragment; AOD-9604 is its modified, tyrosine-extended analog. Both isolate lipolytic activity away from full GH signaling.
Frequently asked questions
What is adipotide (FTPP)?
Adipotide, also called prohibitin-targeting peptide-1 (FTPP), is a synthetic peptidomimetic with two domains: a homing motif (CKGGRAKDC) that targets white-adipose-tissue vasculature and a pro-apoptotic (KLAKLAK)2 moiety. It is studied as a targeted anti-obesity research agent that acts on the blood supply of fat tissue rather than on fat cells directly.
How does adipotide work mechanistically?
The homing peptide is reported to bind a prohibitin/annexin A2 complex on endothelial cells feeding white adipose tissue; the attached pro-apoptotic sequence then triggers apoptosis in those vessels. Disrupting the adipose blood supply causes the fed fat cells to regress, altering lipid uptake, glucose handling, and adipose signaling in models.
What research supports adipotide?
In a primate study, obese rhesus monkeys were reported to lose about 11% of body weight over 28 days with roughly 39% reduction in fat deposits. Rodent work reported similar targeted fat-mass loss. Because its mechanism affects vasculature, kidney-related effects have been a noted concern in the preclinical literature.
What is HGH Fragment 176-191?
HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal lipolytic region (residues 176-191) of human growth hormone (native sequence LRIVQCRSVEGSCGF). Research identified this segment as carrying the fat-mobilizing activity of GH, while the diabetogenic IGF-1-driving activity resides in a different region (roughly 1-43).
How does HGH Fragment 176-191 differ from AOD-9604?
AOD-9604 is a stabilized analog of HGH Fragment 176-191: it adds an N-terminal tyrosine to the native fragment to improve stability and lipolytic activity. HGH Fragment 176-191 is the unmodified sequence. Both are studied for lipolysis, but the raw fragment is less characterized and has a very short duration.
What does the short half-life imply for research design?
The fragment has a very short half-life (reported ~15-20 minutes), which is why research protocols often describe split dosing (e.g., morning and evening) to maintain exposure. Its rapid clearance is an important consideration when designing pharmacodynamic experiments around lipolysis.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.